Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents

Monoclonal (M) protein can be detected in the serum and/or urine of patients with multiple myeloma (MM) as either intact immunoglobulins (Ig) or free light chains (FLC). Current guidelines[1][1] recommend the use of serum and urine electrophoresis plus immunofixation to evaluate and monitor response